What is William Blair’s Forecast for Korro Bio Q1 Earnings?

Korro Bio, Inc. (NASDAQ:KRRO) – Equities research analysts at William Blair issued their Q1 2025 EPS estimates for Korro Bio in a research note issued to investors on Tuesday, March 18th. William Blair analyst M. Minter forecasts that the company will post earnings per share of ($2.91) for the quarter. The consensus estimate for Korro Bio’s current full-year earnings is ($9.52) per share. William Blair also issued estimates for Korro Bio’s Q2 2025 earnings at ($2.98) EPS, Q3 2025 earnings at ($3.02) EPS, Q4 2025 earnings at ($3.05) EPS, FY2025 earnings at ($11.95) EPS, Q1 2026 earnings at ($3.11) EPS, Q2 2026 earnings at ($3.14) EPS, Q3 2026 earnings at ($3.17) EPS, Q4 2026 earnings at ($3.20) EPS and FY2026 earnings at ($12.61) EPS.

Other research analysts also recently issued reports about the stock. Oppenheimer initiated coverage on shares of Korro Bio in a research report on Friday, January 10th. They set an “outperform” rating and a $155.00 price objective for the company. Royal Bank of Canada decreased their target price on shares of Korro Bio from $105.00 to $95.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $115.00 target price on shares of Korro Bio in a research note on Thursday. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $142.57.

Korro Bio Stock Performance

Shares of KRRO opened at $23.76 on Friday. Korro Bio has a one year low of $18.50 and a one year high of $98.00. The firm has a 50 day simple moving average of $29.88 and a two-hundred day simple moving average of $41.39.

Korro Bio (NASDAQ:KRRO) last released its quarterly earnings results on Tuesday, March 18th. The company reported ($2.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.33) by $0.07. The business had revenue of $2.27 million during the quarter.

Institutional Trading of Korro Bio

Institutional investors have recently modified their holdings of the business. AlphaQuest LLC boosted its position in Korro Bio by 23.2% during the fourth quarter. AlphaQuest LLC now owns 2,189 shares of the company’s stock valued at $83,000 after acquiring an additional 412 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Korro Bio by 3.0% during the fourth quarter. Bank of New York Mellon Corp now owns 14,788 shares of the company’s stock valued at $563,000 after acquiring an additional 435 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Korro Bio by 9.0% during the fourth quarter. Bank of America Corp DE now owns 7,037 shares of the company’s stock valued at $268,000 after purchasing an additional 581 shares during the period. Rhumbline Advisers raised its holdings in shares of Korro Bio by 7.8% during the fourth quarter. Rhumbline Advisers now owns 9,602 shares of the company’s stock valued at $366,000 after purchasing an additional 691 shares during the period. Finally, Blair William & Co. IL raised its holdings in shares of Korro Bio by 5.7% during the fourth quarter. Blair William & Co. IL now owns 12,895 shares of the company’s stock valued at $491,000 after purchasing an additional 695 shares during the period. Institutional investors own 13.18% of the company’s stock.

About Korro Bio

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).